首頁 > 市場調查報告書 > 醫療設備

眼科設備醫學影像診斷

市場調查報告書

商品編碼

2126516

視網膜電圖市場：策略性洞察與預測（2026-2031 年）

Electroretinogram Market - Strategic Insights and Forecasts (2026-2031)

出版日期: 2026年08月13日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計視網膜電圖 (ERG) 市場將以 8.8% 的複合年成長率成長，從 2026 年的 8.507 億美元成長到 2031 年的 12.973 億美元。

視網膜電圖（ERG）市場正經歷重大變革，其驅動力包括：視網膜疾病早期檢測的模式轉移、糖尿病相關眼部併發症負擔的日益加重，以及眼科對客觀功能評估需求的成長。這一市場演變的特點在於，人們逐漸認知到ERG檢測能夠提供僅靠結構成像無法獲得的補充功能信息，對於診斷遺傳性視網膜疾病、後續觀察以及在發生不可逆結構損傷之前評估視網膜功能至關重要。先進的電生理技術、攜帶式診斷平台和數位化工作流程的整合，使得視網膜功能檢測更加快速、便利且日益標準化。由於人口老化、糖尿病盛行率上升和預期壽命延長，患者數量不斷增加，醫療系統正在擴大視網膜篩檢項目，從而持續推動對客觀視網膜評估工具的需求。隨著對手持式和可攜式系統、多焦ERG技術和基於軟體的檢查觀察分析平台的大量投資，ERG檢測正在成為現代眼科護理和視網膜疾病管理中的重要組成部分。

市場促進因素

視網膜疾病和糖尿病相關眼部併發症負擔日益加重，是視網膜電圖（ERG）市場的主要促進因素。糖尿病的盛行率在已開發和新興醫療市場均持續上升。糖尿病視網膜病變是可預防性視力喪失最常見的原因之一，因此需要持續監測視網膜健康。雖然影像技術可以提供結構訊息，但ERG檢測提供了一種補充性的功能評估，尤其適用於希望在出現可見解剖結構惡化之前評估視網膜功能的臨床醫生。醫療機構正在擴大視網膜篩檢計畫以應對不斷成長的患者數量，而改進的早期轉診系統也促進了診斷工具的使用，這些工具能夠輔助疾病分類、治療監測和長期患者管理。因此，ERG的使用量持續成長。臨床上對遺傳性視網膜疾病的日益關注，透過對客觀功能評估的需求，進一步加速了市場成長。隨著基因療法的發展和精準醫療的進步，人們對遺傳性視網膜疾病的關注度也不斷提高。視網膜基因治療的臨床試驗需要在治療和監測的各個階段對視網膜功能進行客觀測量。視網膜電圖（ERG）檢測仍然是評估視網膜反應和疾病進展的成熟方法之一。大學附屬醫院、研究機構和視網膜專科中心正在投資先進的電生理技術，以支持不斷擴展的臨床研究計畫。隨著人口老化，眼科醫療服務的擴展對診斷服務的需求持續成長。與老齡化相關的視網膜疾病仍然是診斷需求的重要來源。隨著人口老化，老齡化黃斑部病變、視網膜血管疾病和青光眼等疾病的盛行率正在上升。聯合國預測，未來幾十年全球60歲及以上人口將顯著成長，這將持續增加對眼科診斷服務的需求。攜帶式和分散式診斷工作流程的轉變正在將應用範圍擴展到傳統電生理檢查室之外。儘管傳統的桌上型系統在高級檢測環境中仍然佔據主導地位，但攜帶式和手持式設備正逐漸被推廣應用，應用於兒童診療、社區診所和行動診斷服務等領域。製藥業對視網膜功能終點的日益關注，也推動了製藥公司和學術研究中心對這類設備的需求。

市場限制因素

訓練有素的電生理專家數量有限，限制了檢測能力。準確的ERG檢測需要病患準備、電極放置、訊號解讀和方案標準化的專業知識。先進的系統需要大量的資金投入，可能導致較長的採購週期。全面的ERG平台通常需要專用軟體、專用測試環境、配件和持續的維護支援。報銷方案和臨床應用方面的差異可能會限制設備部署後的使用。不同醫療體系的報銷政策差異顯著。複雜的工作流程和患者檢測要求可能會對兒童、老年和認知障礙患者帶來挑戰。與其他眼科診斷方法的競爭要求供應商清晰地證明其臨床附加價值。

北美洲
- 透過技術
- 依產品
- 透過使用
- 國家
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 透過技術
- 依產品
- 透過使用
- 國家
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 透過技術
- 依產品
- 透過使用
- 國家
  - 英國
  - 德國
  - 法國
  - 西班牙
  - 其他
中東和非洲
- 透過技術
- 依產品
- 透過使用
- 國家
  - 沙烏地阿拉伯
  - UAE
  - 以色列
  - 其他
亞太地區
- 透過技術
- 依產品
- 透過使用
- 國家
  - 日本
  - 中國
  - 印度
  - 韓國
  - 印尼
  - 泰國
  - 其他

第9章：競爭環境與分析

主要公司及策略分析
市佔率分析
合併、收購、協議和合作關係
競爭環境儀錶板

第10章：公司簡介

LKC Technologies
Eye Patient
ICR
WellFirst Health
Neurosoft
Roland Consult
Aetna
USF Health
Medico Electrodes

簡介目錄

Product Code: KSI061616012

The Electroretinogram Market is forecast to grow at a CAGR of 8.8%, reaching USD 1,297.3 million in 2031 from USD 850.7 million in 2026.

The electroretinogram market is undergoing significant transformation driven by the paradigm shift toward early detection of retinal disorders, the growing burden of diabetes-related eye complications, and the increasing demand for objective functional assessment in ophthalmology. The market's evolution is characterized by the recognition that ERG testing provides complementary functional information that structural imaging alone cannot deliver, making it essential for diagnosing inherited retinal diseases, monitoring diabetic retinopathy, and evaluating retinal function before irreversible structural damage occurs. The convergence of advanced electrophysiology technologies, portable diagnostic platforms, and digital workflow integration is enabling faster, more accessible, and increasingly standardized retinal function testing. Healthcare systems are expanding retinal screening programs to address rising patient volumes associated with aging populations, diabetes prevalence, and longer life expectancy, creating sustained demand for objective retinal assessment tools. The market is witnessing significant investment in handheld and portable systems, multifocal ERG technologies, and software-enabled interpretation platforms, positioning ERG testing as a critical component of modern ophthalmic care and retinal disease management.

Market Drivers

The growing burden of retinal disease and diabetes-related eye complications represents the primary driver for the electroretinogram market. The prevalence of diabetes continues to increase across both developed and emerging healthcare markets. Diabetic retinopathy remains one of the most common causes of preventable vision loss and requires ongoing monitoring of retinal health. While imaging technologies provide structural information, ERG testing offers complementary functional assessment, particularly when clinicians seek to evaluate retinal performance before visible anatomical deterioration occurs. Healthcare providers are expanding retinal screening programs to address rising patient volumes, with earlier referral pathways increasing the use of diagnostic tools capable of supporting disease classification, treatment monitoring, and longitudinal patient management, resulting in sustained growth in ERG utilization. The increasing clinical focus on inherited retinal diseases is further accelerating market growth through demand for objective functional assessment. Inherited retinal disorders have received increased attention following progress in gene therapy development and precision medicine. Clinical trials involving retinal gene therapies require objective measurements of retinal function throughout treatment and monitoring phases. ERG testing remains one of the established methods for evaluating retinal response and disease progression. Academic hospitals, research institutions, and specialist retinal centers are investing in advanced electrophysiology capabilities to support expanding clinical research programs. The expansion of ophthalmology services in aging populations is creating sustained demand for diagnostic services. Age-related retinal conditions continue to represent an important source of diagnostic demand. Disorders such as age-related macular degeneration, retinal vascular disease, and glaucoma become more prevalent as populations age. The United Nations projects a substantial increase in the global population aged 60 years and older over the coming decades, creating sustained demand for ophthalmic diagnostic services. The shift toward portable and decentralized diagnostic workflows is expanding deployment environments beyond traditional electrophysiology laboratories. Traditional tabletop systems continue to dominate advanced testing environments, but portable and handheld devices are gaining acceptance in outreach programs, pediatric settings, community clinics, and mobile diagnostic services. Growing pharmaceutical interest in retinal function endpoints is supporting demand from pharmaceutical sponsors and academic research centers.

Market Restraints

Limited availability of trained electrophysiology specialists restricts testing capacity. Accurate ERG testing requires specialized knowledge in patient preparation, electrode placement, signal interpretation, and protocol standardization. High capital investment requirements for advanced systems can lengthen procurement cycles. Comprehensive ERG platforms often require specialized software, dedicated testing environments, accessories, and ongoing maintenance support. Variability in reimbursement and clinical utilization can restrict equipment utilization even after installation. Reimbursement policies differ substantially across healthcare systems. Workflow complexity and patient testing requirements may present challenges for pediatric, elderly, and cognitively impaired patients. Competition from alternative ophthalmic diagnostic modalities requires suppliers to clearly demonstrate incremental clinical value.

Technology and Product Insights

The technology landscape is characterized by the growing importance of portable systems, multifocal ERG, and software-enabled interpretation. Clinical diagnostics represents the most commercially important application segment because most equipment purchases are ultimately driven by patient care requirements rather than research activity alone. Hospitals, ophthalmology clinics, retinal specialty centers, and academic medical institutions depend on objective retinal function testing to support diagnosis, treatment planning, and disease monitoring. Healthcare providers evaluate workflow efficiency, testing consistency, patient comfort, software functionality, report generation capabilities, and service support. As patient volumes increase, providers increasingly favor systems that reduce technician workload while maintaining diagnostic accuracy. The segment analysis reveals that clinical buyers place greater emphasis on operational reliability, regulatory compliance, and long-term service availability compared with research applications. The segment benefits from expanding use in complex retinal disease management, including inherited retinal disorders, retinal toxicity monitoring, diabetic retinal complications, and selected glaucoma assessments. North America remains an important market due to advanced ophthalmology infrastructure, strong clinical research activity, and broad access to specialist care, with the United States accounting for the majority of regional demand. Europe benefits from established retinal disease management pathways and widespread adoption of evidence-based ophthalmic care. Asia Pacific presents substantial long-term opportunities due to large patient populations and increasing incidence of diabetes-related eye disease. The integration of software and digital workflows is becoming increasingly important as providers seek systems that reduce technician workload while maintaining diagnostic accuracy.

Competitive and Strategic Outlook

The competitive landscape is characterized by specialized electrophysiology technology providers where competition centers on test accuracy, software capabilities, portability, ease of use, and support for multiple ERG modalities. LKC Technologies, Roland Consult, Neurosoft, and Medico Electrodes participate directly in equipment, accessories, or electrophysiology-related solutions. Organizations such as Eye Patient, WellFirst Health, Aetna, and USF Health influence the broader ecosystem through healthcare delivery, reimbursement, patient management, research collaboration, or clinical service activities. ICR participates in the research and clinical environment supporting retinal assessment activities. Across the market, suppliers increasingly focus on workflow simplification, digital reporting capabilities, and improved patient comfort, with service quality remaining a key differentiator because healthcare providers often require long equipment lifecycles and dependable technical support. Barriers to entry remain moderate to high, with clinical validation requirements, regulatory compliance obligations, specialist customer expectations, and the need for established service networks creating challenges for new entrants. Customer switching costs are elevated in institutions where testing protocols, software systems, and clinical workflows have already been standardized. Recent key developments include AMETEK acquiring LKC Technologies, a leading electroretinography developer best known for its handheld RETeval ERG platform, expanding AMETEK's ophthalmic diagnostics portfolio and strengthening its retinal-function testing capabilities. Following its acquisition, LKC Technologies confirmed continued investment in RETeval electroretinography solutions, supporting broader commercialization, innovation, and global expansion of portable retinal-function diagnostics. RetMap obtained FDA clearance for its updated RM Electrode, designed for electroretinography signal recording, improving multifocal ERG testing usability and electrode-orientation identification.

Short Conclusion

The electroretinogram market is positioned for sustained growth driven by the convergence of retinal disease burden, technological innovation, and expanding ophthalmic services. The transition from traditional tabletop systems toward portable and integrated diagnostic platforms represents a fundamental shift in retinal function assessment. While challenges related to specialist availability, capital investment, and reimbursement variability persist, strategic investments in portability, workflow efficiency, and clinical evidence are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with ERG testing evolving into a critical component of modern ophthalmic care, supporting earlier diagnosis, treatment monitoring, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View

5. ELECTRORETINOGRAM MARKET, BY TECHNOLOGY

5.1. Introduction
5.2. Full-Field Flash ERG (ffERG)
- 5.2.1. Market Trends and Opportunities
- 5.2.2. Growth Prospects
- 5.2.3. Geographic Lucrativeness
5.3. Pattern ERG (PERG)
- 5.3.1. Market Trends and Opportunities
- 5.3.2. Growth Prospects
- 5.3.3. Geographic Lucrativeness
5.4. Multifocal ERG (mfERG)
- 5.4.1. Market Trends and Opportunities
- 5.4.2. Growth Prospects
- 5.4.3. Geographic Lucrativeness

6. ELECTRORETINOGRAM MARKET, BY PRODUCT

6.1. Introduction
6.2. Handheld
- 6.2.1. Market Trends and Opportunities
- 6.2.2. Growth Prospects
- 6.2.3. Geographic Lucrativeness
6.3. Tabletop
- 6.3.1. Market Trends and Opportunities
- 6.3.2. Growth Prospects
- 6.3.3. Geographic Lucrativeness

7. ELECTRORETINOGRAM MARKET, BY APPLICATION

7.1. Introduction
7.2. Clinical Diagnostics
- 7.2.1. Market Trends and Opportunities
- 7.2.2. Growth Prospects
- 7.2.3. Geographic Lucrativeness
7.3. Research
- 7.3.1. Market Trends and Opportunities
- 7.3.2. Growth Prospects
- 7.3.3. Geographic Lucrativeness

8. ELECTRORETINOGRAM MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Technology
- 8.2.2. By Product
- 8.2.3. By Application
- 8.2.4. By Country
  - 8.2.4.1. United States
    - 8.2.4.1.1. Market Trends and Opportunities
    - 8.2.4.1.2. Growth Prospects
  - 8.2.4.2. Canada
    - 8.2.4.2.1. Market Trends and Opportunities
    - 8.2.4.2.2. Growth Prospects
  - 8.2.4.3. Mexico
    - 8.2.4.3.1. Market Trends and Opportunities
    - 8.2.4.3.2. Growth Prospects
8.3. South America
- 8.3.1. By Technology
- 8.3.2. By Product
- 8.3.3. By Application
- 8.3.4. By Country
  - 8.3.4.1. Brazil
    - 8.3.4.1.1. Market Trends and Opportunities
    - 8.3.4.1.2. Growth Prospects
  - 8.3.4.2. Argentina
    - 8.3.4.2.1. Market Trends and Opportunities
    - 8.3.4.2.2. Growth Prospects
  - 8.3.4.3. Others
    - 8.3.4.3.1. Market Trends and Opportunities
    - 8.3.4.3.2. Growth Prospects
8.4. Europe
- 8.4.1. By Technology
- 8.4.2. By Product
- 8.4.3. By Application
- 8.4.4. By Country
  - 8.4.4.1. United Kingdom
    - 8.4.4.1.1. Market Trends and Opportunities
    - 8.4.4.1.2. Growth Prospects
  - 8.4.4.2. Germany
    - 8.4.4.2.1. Market Trends and Opportunities
    - 8.4.4.2.2. Growth Prospects
  - 8.4.4.3. France
    - 8.4.4.3.1. Market Trends and Opportunities
    - 8.4.4.3.2. Growth Prospects
  - 8.4.4.4. Spain
    - 8.4.4.4.1. Market Trends and Opportunities
    - 8.4.4.4.2. Growth Prospects
  - 8.4.4.5. Others
    - 8.4.4.5.1. Market Trends and Opportunities
    - 8.4.4.5.2. Growth Prospects
8.5. Middle East and Africa
- 8.5.1. By Technology
- 8.5.2. By Product
- 8.5.3. By Application
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
    - 8.5.4.1.1. Market Trends and Opportunities
    - 8.5.4.1.2. Growth Prospects
  - 8.5.4.2. UAE
    - 8.5.4.2.1. Market Trends and Opportunities
    - 8.5.4.2.2. Growth Prospects
  - 8.5.4.3. Israel
    - 8.5.4.3.1. Market Trends and Opportunities
    - 8.5.4.3.2. Growth Prospects
  - 8.5.4.4. Others
    - 8.5.4.4.1. Market Trends and Opportunities
    - 8.5.4.4.2. Growth Prospects
8.6. Asia Pacific
- 8.6.1. By Technology
- 8.6.2. By Product
- 8.6.3. By Application
- 8.6.4. By Country
  - 8.6.4.1. Japan
    - 8.6.4.1.1. Market Trends and Opportunities
    - 8.6.4.1.2. Growth Prospects
  - 8.6.4.2. China
    - 8.6.4.2.1. Market Trends and Opportunities
    - 8.6.4.2.2. Growth Prospects
  - 8.6.4.3. India
    - 8.6.4.3.1. Market Trends and Opportunities
    - 8.6.4.3.2. Growth Prospects
  - 8.6.4.4. South Korea
    - 8.6.4.4.1. Market Trends and Opportunities
    - 8.6.4.4.2. Growth Prospects
  - 8.6.4.5. Indonesia
    - 8.6.4.5.1. Market Trends and Opportunities
    - 8.6.4.5.2. Growth Prospects
  - 8.6.4.6. Thailand
    - 8.6.4.6.1. Market Trends and Opportunities
    - 8.6.4.6.2. Growth Prospects
  - 8.6.4.7. Others
    - 8.6.4.7.1. Market Trends and Opportunities
    - 8.6.4.7.2. Growth Prospects